



## **Soleno Therapeutics to Participate in the BIO CEO & Investor Conference**

February 8, 2022

REDWOOD CITY, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the BIO CEO & Investor Conference on Tuesday, February 15, 2022 at 2:15 PM Eastern Time.

### **About Soleno Therapeutics, Inc.**

Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase 3 clinical development program. For more information, please visit [www.soleno.life](http://www.soleno.life).

### **Corporate Contact:**

Brian Ritchie  
LifeSci Advisors, LLC  
212-915-2578



Source: Soleno Therapeutics